Dr. Atul Mahableshwarkar, hired last summer by BlackThorn Therapeutics as vice president of clinical development, talks about the South San Francisco drug company's attack on depression.

What an emerging drug company is doing to disrupt depression

BioFlash is a biweekly podcast, hosted by San Francisco Business Times biotech reporter Ron Leuty. From cancer immunotherapy to drug pricing, we explore the hot topics driving the life sciences ecosystem in the San Francisco Bay Area and beyond.

Share What an emerging drug company is doing to disrupt depression

Sign up to save your podcasts

What an emerging drug company is doing to disrupt depression

What an emerging drug company is doing to disrupt depression